Peptides DB
Research-centric peptide and protocol reference hub
Study 28 of 28HMG (Human Menopausal Gonadotropin) literatureEuropean journal of obstetrics, gynecology, and reproductive biology · Observational2026

Follitropin delta versus human menopausal gonadotropin in progestin protocol cycles: a retrospective cohort study using inverse probability of treatment weighting.

Follitropin delta showed a higher oocyte yield but did not significantly improve cumulative ongoing pregnancy rates compared to human menopausal gonadotropin in progestin protocol cycles.

Read at European journal of obstetrics, gynecology, and reproductive biologyAdd to compare

Where it sits

this study against the rest of the hmg (human menopausal gonadotropin) corpus
1
Preclinical
21
Observational · this one
0
Open-label
3
Randomised
3
Reviews

Summary and findings

This study compared follitropin delta (FD) and human menopausal gonadotropin (hMG) in progestin protocol cycles to assess cumulative ongoing pregnancy outcomes. A total of 716 cycles were analyzed, with 382 receiving FD and 334 receiving hMG. The findings indicated that FD resulted in a higher number of retrieved oocytes with lower gonadotropin consumption, but cumulative ongoing pregnancy rates were similar between the two groups.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
FD yielded more retrieved oocytes than hMG (adjusted mean difference 2.11; 95% CI 0.57-3.65)n=7162026

Abstract

The authors’ words, as European journal of obstetrics, gynecology, and reproductive biology supplied them

<h4>Objective</h4>To determine whether follitropin delta (FD), administered using an individualized dosing algorithm, improves cumulative ongoing pregnancy compared with human menopausal gonadotropin (hMG) in progestin protocol (PP) cycles.<h4>Study design</h4>Retrospective cohort study of 716 progestin protocol (PP) stimulation cycles (382 FD, 334 hMG) at one center (oocyte retrieval April 2022-January 2024; follow-up to July 2024). All started cycles reached retrieval. Inverse probability of treatment weighting (IPTW) was the primary analysis; 1:1 propensity score matching was a sensitivity analysis. The primary outcome was cumulative ongoing pregnancy per retrieval (per started cycle) from all frozen embryo transfers (FET).<h4>Results</h4>After IPTW, covariates were balanced. FD yielded more retrieved oocytes than hMG (adjusted mean difference 2.11; 95% confidence interval [CI] 0.57-3.65) with lower gonadotropin consumption; mature (MII) oocytes, fertilized oocytes, and blastocysts did not differ. At first FET (n = 558), hCG positivity was lower with FD (65.0% vs 74.6%; odds ratio [OR] 0.63, 95% CI 0.41-0.98; P = 0.041); clinical pregnancy (51.6% vs 61.4%; P = 0.057) and ongoing pregnancy (39.4% vs 46.7%; P = 0.175) were numerically lower but not significantly so. Cumulative ongoing pregnancy per retrieval was similar (50.2% vs 50.5%; OR 0.99, 95% CI 0.66-1.47).<h4>Conclusion(s)</h4>FD gave a higher oocyte yield with lower gonadotropin consumption than hMG, without a significant increase in MII oocytes or blastocysts. FD was associated with lower hCG positivity and numerically lower clinical pregnancy after the first FET, whereas cumulative ongoing pregnancy per retrieval did not differ significantly. Caution is warranted; prospective studies with live birth endpoints are needed.

Background

This paper addresses the effectiveness of follitropin delta (FD) compared to human menopausal gonadotropin (hMG) in progestin protocol cycles for fertility treatment. Previous studies have indicated varying outcomes with different gonadotropin formulations, but there is limited data specifically comparing FD and hMG in this context. Understanding the differences in outcomes, particularly regarding pregnancy rates, is essential for optimizing fertility treatments.

Methods

This was a retrospective cohort study involving 716 progestin protocol stimulation cycles, with 382 cycles receiving FD and 334 receiving hMG. The primary outcome measured was cumulative ongoing pregnancy per retrieval from all frozen embryo transfers (FET). The analysis utilized inverse probability of treatment weighting (IPTW) for the primary analysis, with 1:1 propensity score matching as a sensitivity analysis.

Results

The primary endpoint indicated that FD yielded more retrieved oocytes than hMG, with an adjusted mean difference of 2.11 (95% CI 0.57-3.65). At the first FET, hCG positivity was significantly lower with FD (65.0% vs 74.6%; OR 0.63, 95% CI 0.41-0.98; P=0.041). Clinical pregnancy rates were 51.6% for FD compared to 61.4% for hMG (P=0.057), while ongoing pregnancy rates were 39.4% for FD versus 46.7% for hMG (P=0.175). Cumulative ongoing pregnancy per retrieval was similar between groups (50.2% for FD vs 50.5% for hMG; OR 0.99, 95% CI 0.66-1.47).

Interpretation

The findings suggest that while FD may provide a higher yield of retrieved oocytes, the differences in pregnancy outcomes were not statistically significant. The lower hCG positivity and clinical pregnancy rates associated with FD raise questions about its efficacy compared to hMG. Limitations such as the retrospective design and single-center nature of the study may confound the conclusions drawn, indicating a need for caution in interpreting the results.

Key findings

  • FD yielded more retrieved oocytes than hMG (adjusted mean difference 2.11; 95% CI 0.57-3.65)
  • At first FET (n=558), hCG positivity was lower with FD (65.0% vs 74.6%; OR 0.63, 95% CI 0.41-0.98; P=0.041)
  • Clinical pregnancy rates were 51.6% for FD vs 61.4% for hMG (P=0.057)
  • Ongoing pregnancy rates were 39.4% for FD vs 46.7% for hMG (P=0.175)
  • Cumulative ongoing pregnancy per retrieval was similar (50.2% for FD vs 50.5% for hMG; OR 0.99, 95% CI 0.66-1.47)

Limitations

  • retrospective study design
  • single-center analysis
  • no live birth endpoints reported
  • potential for selection bias

Elsewhere in the HMG (Human Menopausal Gonadotropin) corpus

C<i>Ficus elastica</i> phytochemicals mitigate hyperlipidemia <i>via</i> potential HMG-CoA reductase inhibition, reduced oxidative stress, and tissue preservation.Research in pharmaceutical sciences · 2026 · Not reported in abstract.AnimalCsox17 Mutagenesis Reveals Compounding Effects ofMaternal and Zygotic Contribution on Microglia Abundance.Glia · 2026 · Not reported in abstract.AnimalBReal-world utilization of gonadotropins and the associated cumulative live birth rates in the United States: a retrospective claims database analysis.Journal of medical economics · 2026 · n=14174 · Adjusted odds of live birth were 1.31 (95% CI: 1.20-1.45) for mixed protocol compared to follitropin alfa.reviewCMetabolomics-based screening identifies Aspergillus strains that accumulate bioactive leucine catabolites and fatty acid ethyl esters in koji mold-ripened cheese.Food research international (Ottawa, Ont.) · 2026 · R > 0.975 correlation between production quantity of HMB, HMG, α-ketoisocaproic acid, and isovaleric acid with initial concentration of l-leucine.In vitroBIs there a difference in ovarian hyperstimulation syndrome rates in freeze-all treatment cycles in high-risk patients treated with different GnRH agonist triggers?Human fertility (Cambridge, England) · 2026 · n=333 · 12-fold increased risk of severe OHSS with Triptorelin-MR compared to other preparations.HumanCA gut microbial odd-chain fatty acid alleviates atherosclerosis in mice.Nature · 2026Animal